- Amended Current report filing (8-K/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

(Amendment No. 1)

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  May 17, 2010

 

TIENS BIOTECH GROUP (USA), INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware		001-32477		75-2926439
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification Number)

 

No. 6, Yuanquan Road, Wuqing New-Tech Industrial Park, Tianjin, China 301700

 

(Address of principal executive offices)

 

Registrant's telephone number, including area code:  (86)   22 - 8213-7335

Not applicable

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

 

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o	Soliciting materials pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

---

 

Explanatory Note

 

This Amendment No. 1 to the registrant’s Form 8-K, filed with the Securities and Exchange Commission on May 17, 2010, replaces exhibit 99.1 to the 8-K.  No other changes are made to the registrant’s Form 8-K.

 

Item 2.02  Results of Operations and Financial Condition.

 

On May 17, 2010, Tiens Biotech Group (USA), Inc. (the “Company”) issued a press release reporting the Company’s financial results for the fiscal quarter ended March 31, 2010.  The full text of the press release is set forth in Exhibit 99.1 attached hereto.

 

Item 9.01  Financial Statements and Exhibits.

 

(d)            Exhibits .

 

Exhibit Number	Description
99.1	Press release, dated May 17, 2010.

 

2

---

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	TIENS BIOTECH GROUP (USA), INC.
Date:  May 19, 2010	By:	/s/ Manbo He
		Name:   Manbo He
		Title:     Chief Financial Officer

 

3

---

 

Exhibits

 

Exhibit Number	Description
99.1	Press release, dated May 17, 2010.

 

4

---